There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for DexCom Inc. (DXCM) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$3.62, or -4.14%, to $83.75. Volume reached 197,879 shares, with price reaching a high of $85.25 and a low of $83. Earlier, Yahoo Finance discussed this stock as it revealed Dexcom Announces Upcoming Conference Presentations.
This NASDAQ-listed company operates within the Diagnostics & Research industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $84.46 and fluctuated between $88.64 as its day high and $84.42 as its day low. The current market capitalization of DexCom Inc. is $33.49B. A total of 2.25 million shares were traded on the day, compared to an average of 2.60M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, DXCM has seen 0 BUY and 4 SELL insider trades, representing the acquisition of 0 and the disposition of 3,005 shares. Over the last 12 months, there were 39 BUYs and 172 SELLs from insiders. Insiders purchased 155,883 shares during that period but sold 130,088.
In the most recent transaction, Dolan Matthew Vincent sold 5 shares of DXCM for 81.63 per share on Sep 01. After the transaction, the SVP Corporate Strategy-Develop now owns 26,536 company shares. In a previous transaction on Aug 23, Pacelli Steven Robert sold 1,000 shares at 84.21 per share. DXCM shares that EVP Managing Director Dexcom V owns now total 137,700.
Among the insiders who sold shares, Pacelli Steven Robert disposed of 1,000 shares on Jul 25 at a per-share price of $83.07. This resulted in the EVP Managing Director Dexcom V holding 138,700 shares of DXCM after the transaction. In another insider transaction, Pacelli Steven Robert sold 1,000 shares at $72.55 per share on Jun 23. Company shares held by the EVP Managing Director Dexcom V now total 139,700.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DXCM in the last 3 months, the mean price target is $99.80 with high estimates of $112.00 and low estimates of $83.00. In terms of 52-week highs and lows, DXCM has a high of $164.86 and a low of $66.89.
As of this writing, DXCM has an earnings estimate of $0.24 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of $0.27 per share and a lower estimate of $0.21.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 18 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DXCM is Underweight with a score of 4.79. A total of 12 analysts rated the stock as Buy while 3 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.